Literature DB >> 12762834

Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy.

Narin Apisarnthanarax1, Chul S Ha, Madeleine Duvic.   

Abstract

Follicular mucinosis is a tissue reaction pattern characterized by mucin deposition with follicular sebaceous units and is found as an idiopathic, primary, benign process (alopecia mucinosa), or as a secondary process due to inflammatory and neoplastic disorders (mycosis fungoides). When associated with follicular mucinosis, mycosis fungoides commonly pursues an aggressive course, often undergoing large-cell transformation, which is associated with resistance to therapy and poor prognosis. We present a case of mycosis fungoides with follicular mucinosis that was treated with incomplete courses of interferon, isotretinoin, and polychemotherapy with subsequent rapid progression to tumor-stage mycosis fungoides with large cell transformation and nodal and bone marrow involvement. In this setting, the patient was treated with local radiation therapy, total-skin electron beam therapy, and therapy and maintenance with the oral retinoid-X-receptor retinoid bexarotene, and achieved a durable complete remission.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12762834     DOI: 10.2165/00128071-200304060-00006

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  2 in total

1.  Combination of low-dose total skin electron beam therapy and subsequent localized skin electron beam therapy as a therapeutic option for advanced-stage mycosis fungoides.

Authors:  M Kinoshita-Ise; T Ouchi; E Izumi; O Kawaguchi; K Nagao; M Amagai; T Funakoshi
Journal:  Clin Exp Dermatol       Date:  2017-12-21       Impact factor: 3.470

2.  Dopamine receptor D2 activation suppresses the radiosensitizing effect of aripiprazole via activation of AMPK.

Authors:  Hyounji Lee; Seongman Kang; Jong Kyung Sonn; Young-Bin Lim
Journal:  FEBS Open Bio       Date:  2019-07-23       Impact factor: 2.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.